This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hajjar, R. J. Articles by Leopold, J. A. Search for Related Content PubMed PubMed Citation Articles by Hajjar, R. J. Articles by Leopold, J. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ALLOPURINOL Medline Plus Health Information Cardiomyopathy Heart Failure Related Collections Related Article

(Circulation Research. 2006;98:169.)
© 2006 American Heart Association, Inc.

Editorials

Xanthine Oxidase Inhibition and Heart Failure

Novel Therapeutic Strategy for Ventricular Dysfunction?

Roger J. Hajjar, Jane A. Leopold

From the Division of Cardiology at Massachusetts General Hospital (R.J.H.) and the Cardiology Division, Department of Medicine, Brigham & Women’s Hospital (J.A.L.), Harvard Medical School, Boston, Mass.

Correspondence to Roger J. Hajjar MD, Massachusetts General Hospital, Cardiovascular Research Center, 149 13^th Street, Room 4215, Charlestown, MA 02129. E-mail rhajjar@partners.org

See related article, pages 271–279

Key Words: xanthine oxidase • reactive oxygen species • heart failure • contractility

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Myocardial dysfunction and heart failure perturb cardiovascular homeostatic signaling pathways as well as initiate a program of molecular, biochemical, and structural modifications to remodel the failing ventricle. Accumulating evidence suggests that the cardiovascular redox state plays an integral role in these processes. In fact, in the failing heart, elevated levels of reactive oxygen species (ROS) and cardiomyocyte oxidant stress are associated with maladaptive ventricular remodeling and a progressive decline in cardiovascular function.

The association between ROS and heart failure has been established. Increased indices of oxidant stress have been measured in patients with congestive heart failure. In clinical studies, patients with heart failure were found to have evidence of lipid peroxidation and elevated 8-iso-prostaglandin F₂ levels^1–4 whereas in experimental models of heart failure, investigators have been able to directly measure increased ROS production from cardiomyocytes.^5,6 These findings have been corroborated in studies that measured ROS levels in explanted human hearts at the time of transplant.⁷ Furthermore, a number of neurohormonal and mechanical stressors that are associated with the heart failure phenotype augment ROS generation.^8,9 Prolonged exposure to ROS, in turn, results in cardiomyocyte dysfunction.¹⁰

At a cellular level, elevated levels of ROS impair cardiomyocyte function by damaging ion channels as well as inhibiting contractility. ROS disrupt the structural integrity of ion channels via membrane lipid peroxidation.^2,11 ROS also decrease expression and activity of the sarcoplasmic reticulum Ca²⁺ ATPase SERCA2,¹² which is critical for effective cardiac calcium handling. Interestingly, ROS have also been shown to decrease myofilament calcium sensitivity by activation . . . [Full Text of this Article]

Related Article:

Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy

Khalid M. Minhas, Roberto M. Saraiva, Karl H. Schuleri, Stephanie Lehrke, Meizi Zheng, Anastasios P. Saliaris, Cristine E. Berry, Konrad M. Vandegaer, Dechun Li, and Joshua M. Hare
Circ. Res. 2006 98: 271-279. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				T. Ohtsubo, K. Matsumura, K. Sakagami, K. Fujii, K. Tsuruya, H. Noguchi, I. I. Rovira, T. Finkel, and M. Iida Xanthine Oxidoreductase Depletion Induces Renal Interstitial Fibrosis Through Aberrant Lipid and Purine Accumulation in Renal Tubules Hypertension, October 1, 2009; 54(4): 868 - 876. [Abstract] [Full Text] [PDF]

				C. Bergamini, M. Cicoira, A. Rossi, and C. Vassanelli Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure Eur J Heart Fail, May 1, 2009; 11(5): 444 - 452. [Abstract] [Full Text] [PDF]

				E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama Role of Xanthine Oxidoreductase in the Reversal of Diastolic Heart Failure by Candesartan in the Salt-Sensitive Hypertensive Rat Hypertension, October 1, 2007; 50(4): 657 - 662. [Abstract] [Full Text] [PDF]